InterMune
2Q Revenues: $24.1 million (-10%)
2Q Loss: $44 million* (loss of $23.7 million in 2Q2005)
YTD Revenues: $48.5 million (-12%)
YTD Loss: $56.8 million (loss of 41.1 million YTD2005)
Comments: Revenues for the quarter were comprised solely of Actimmune sales. 2Q2005 revenues consisted of Actimmune and Aralast sales. The company stopped co-promoting Aralast in December 2005. R&D expense for quarter was $24.8 million, up 38%
*Results for the quarter include a $30 million reserve related to a proposed settlement with the government regarding promotional activities for Actimmune.
Magazine
